The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 16, 2016
Filed:
Jan. 17, 2014
Gilbert Besong, Cambridge, GB;
Christopher Thomas Brain, Cambridge, MA (US);
Clinton a Brooks, Beaufort, NC (US);
Miles Stuart Congreve, Cambridge, GB;
Claudio Dagostin, Cambridge, GB;
Guo He, Cambridge, MA (US);
Ying Hou, Cambridge, MA (US);
Steven Howard, Cambridge, GB;
Yue LI, Shanghai, CN;
Yipin LU, Emeryville, CA (US);
Paul Mortenson, Cambridge, GB;
Troy Smith, Cambridge, MA (US);
Moo Je Sung, Cambridge, MA (US);
Steven Woodhead, Cambridge, GB;
Wojciech Wrona, Waltham, MA (US);
Bharat Lagu, Cambridge, MA (US);
Gilbert Besong, Cambridge, GB;
Christopher Thomas Brain, Cambridge, MA (US);
Clinton A Brooks, Beaufort, NC (US);
Miles Stuart Congreve, Cambridge, GB;
Claudio Dagostin, Cambridge, GB;
Guo He, Cambridge, MA (US);
Ying Hou, Cambridge, MA (US);
Steven Howard, Cambridge, GB;
Yue Li, Shanghai, CN;
Yipin Lu, Emeryville, CA (US);
Paul Mortenson, Cambridge, GB;
Troy Smith, Cambridge, MA (US);
Moo Je Sung, Cambridge, MA (US);
Steven Woodhead, Cambridge, GB;
Wojciech Wrona, Waltham, MA (US);
Bharat Lagu, Cambridge, MA (US);
Novartis AG, Basel, CH;
Astex Therapeutics, Ltd., Cambridge, GB;
Abstract
The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.